BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16596397)

  • 1. Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity.
    Song W; McDonald J; Camarda V; Calo G; Guerrini R; Marzola E; Thompson JP; Rowbotham DJ; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2006 May; 373(2):148-57. PubMed ID: 16596397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.
    Camarda V; Song W; Marzola E; Spagnol M; Guerrini R; Salvadori S; Regoli D; Thompson JP; Rowbotham DJ; Behm DJ; Douglas SA; Calo' G; Lambert DG
    Eur J Pharmacol; 2004 Sep; 498(1-3):83-6. PubMed ID: 15363979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.
    Behm DJ; Stankus G; Doe CP; Willette RN; Sarau HM; Foley JJ; Schmidt DB; Nuthulaganti P; Fornwald JA; Ames RS; Lambert DG; Calo' G; Camarda V; Aiyar NV; Douglas SA
    Br J Pharmacol; 2006 May; 148(2):173-90. PubMed ID: 16547525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).
    Camarda V; Spagnol M; Song W; Vergura R; Roth AL; Thompson JP; Rowbotham DJ; Guerrini R; Marzola E; Salvadori S; Cavanni P; Regoli D; Douglas SA; Lambert DG; Calò G
    Br J Pharmacol; 2006 Jan; 147(1):92-100. PubMed ID: 16273120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new ligand for the urotensin II receptor.
    Camarda V; Guerrini R; Kostenis E; Rizzi A; Calò G; Hattenberger A; Zucchini M; Salvadori S; Regoli D
    Br J Pharmacol; 2002 Oct; 137(3):311-4. PubMed ID: 12237249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.
    Patacchini R; Santicioli P; Giuliani S; Grieco P; Novellino E; Rovero P; Maggi CA
    Br J Pharmacol; 2003 Dec; 140(7):1155-8. PubMed ID: 14645137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors.
    Herold CL; Behm DJ; Buckley PT; Foley JJ; Wixted WE; Sarau HM; Douglas SA
    Br J Pharmacol; 2003 May; 139(2):203-7. PubMed ID: 12770925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urotensin-II receptor ligands. From agonist to antagonist activity.
    Grieco P; Carotenuto A; Campiglia P; Marinelli L; Lama T; Patacchini R; Santicioli P; Maggi CA; Rovero P; Novellino E
    J Med Chem; 2005 Nov; 48(23):7290-7. PubMed ID: 16279788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.
    Kitayama M; Barnes TA; Carra G; McDonald J; Calo G; Guerrini R; Rowbotham DJ; Smith G; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Dec; 368(6):528-37. PubMed ID: 14598020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histamine H3-receptor-mediated [35S]GTP gamma[S] binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors.
    Rouleau A; Ligneau X; Tardivel-Lacombe J; Morisset S; Gbahou F; Schwartz JC; Arrang JM
    Br J Pharmacol; 2002 Jan; 135(2):383-92. PubMed ID: 11815373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist.
    Behm DJ; Herold CL; Ohlstein EH; Knight SD; Dhanak D; Douglas SA
    Br J Pharmacol; 2002 Oct; 137(4):449-58. PubMed ID: 12359626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor.
    Olianas MC; Maullu C; Onali P
    Br J Pharmacol; 1997 Oct; 122(3):401-8. PubMed ID: 9351494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-Desmethylclozapine, a major clozapine metabolite, acts as a selective and efficacious delta-opioid agonist at recombinant and native receptors.
    Onali P; Olianas MC
    Neuropsychopharmacology; 2007 Apr; 32(4):773-85. PubMed ID: 16841075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationship study on Tyr9 of urotensin-II(4-11): identification of a partial agonist of the UT receptor.
    Batuwangala M; Camarda V; McDonald J; Marzola E; Lambert DG; Ng LL; Calo' G; Regoli D; Trapella C; Guerrini R; Salvadori S
    Peptides; 2009 Jun; 30(6):1130-6. PubMed ID: 19463746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists.
    Rossowski WJ; Cheng BL; Taylor JE; Datta R; Coy DH
    Eur J Pharmacol; 2002 Mar; 438(3):159-70. PubMed ID: 11909607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.
    Douglas SA; Behm DJ; Aiyar NV; Naselsky D; Disa J; Brooks DP; Ohlstein EH; Gleason JG; Sarau HM; Foley JJ; Buckley PT; Schmidt DB; Wixted WE; Widdowson K; Riley G; Jin J; Gallagher TF; Schmidt SJ; Ridgers L; Christmann LT; Keenan RM; Knight SD; Dhanak D
    Br J Pharmacol; 2005 Jul; 145(5):620-35. PubMed ID: 15852036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro siRNA-mediated knockdown of the UT receptor: implications of density on the efficacy of a range of UT ligands.
    Hunt BD; Ng LL; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Jun; 385(6):651-6. PubMed ID: 22315015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist.
    Chatenet D; Dubessy C; Boularan C; Scalbert E; Pfeiffer B; Renard P; Lihrmann I; Pacaud P; Tonon MC; Vaudry H; Leprince J
    J Med Chem; 2006 Nov; 49(24):7234-8. PubMed ID: 17125276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of adenylate cyclase by human recombinant sst5 receptors expressed in CHO-K1 cells and involvement of Galphas proteins.
    Carruthers AM; Warner AJ; Michel AD; Feniuk W; Humphrey PP
    Br J Pharmacol; 1999 Mar; 126(5):1221-9. PubMed ID: 10205012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors.
    Behm DJ; Herold CL; Camarda V; Aiyar NV; Douglas SA
    Eur J Pharmacol; 2004 May; 492(2-3):113-6. PubMed ID: 15178353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.